Physician profile
Michael E Levin
NPI 1740280452
$5,475.35
in general payments reported to CMS, 2019-2025
36 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $76.19 · 2021: $297 · 2022: $2,223 · 2023: $793 · 2024: $733 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $1,875.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $482.35 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $331.00 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $325.35 | 2021-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $202.96 | 2019-2025 | Erleada |
| Procept Biorobotics Corporation | $175.81 | 2022-2024 | Aquabeam System |
| Laborie Medical Technologies Corp. | $158.89 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Boston Scientific Corporation | $147.54 | 2019-2025 | Spaceoar Vue System - 10ml, Lithovue, Rezum Generator |
| Astellas Pharma US INC | $139.54 | 2019-2023 | Xtandi, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $132.88 | 2021 | |
| Agiliti Surgical, INC. | $131.01 | 2023 | Soltive |
| Dendreon Pharmaceuticals LLC | $129.93 | 2019-2025 | Provenge |
| Urogen Pharma, INC. | $124.98 | 2023-2025 | Jelmyto |
| Amgen INC. | $110.50 | 2019-2023 | Prolia |
| Ferring Pharmaceuticals INC. | $106.36 | 2024-2025 | Adstiladrin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $104.54 | 2019-2025 | Posluma |
| Tempus Ai, INC | $98.84 | 2025 | Xt Cdx |
| Abbvie INC. | $70.75 | 2019-2024 | |
| Myovant Sciences INC. | $69.53 | 2022 | |
| Coloplast Corp | $68.47 | 2021-2025 | Speedicath |
| Calyxo, INC. | $56.41 | 2023-2025 | Cvac Aspiration System |
| Progenics Pharmaceuticals, INC. | $56.15 | 2023-2025 | Pylarify |
| Pfizer INC. | $53.41 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $41.72 | 2019-2023 | Yonsa |
| Olympus America INC. | $36.29 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $32.37 | 2020-2021 | |
| Allergan, INC. | $31.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.74 | 2024 | |
| Novo Nordisk INC | $30.55 | 2025 | Rivfloza |
| Bioprotect Medical, INC. | $24.00 | 2025 | Bioprotect Balloon Implant System |
| Koelis INC. | $22.06 | 2023 | |
| Myriad Genetic Laboratories, INC. | $18.81 | 2024 | Prolaris |
| Accord Healthcare, INC. | $15.28 | 2023 | |
| Neotract INC. | $14.45 | 2020 | |
| Cook Medical LLC | $13.99 | 2025 | Cook |
| Convatec INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.